ReNeuron Group plc (LON:RENE) Stock Rating Reaffirmed by Stifel Nicolaus

ReNeuron Group plc (LON:RENE)‘s stock had its “buy” rating reissued by stock analysts at Stifel Nicolaus in a report released on Thursday, November 9th. They presently have a GBX 13 ($0.17) price target on the stock.

Separately, N+1 Singer reaffirmed a “corporate” rating on shares of ReNeuron Group in a research report on Monday, October 9th.

ReNeuron Group (LON:RENE) traded down GBX 0.03 ($0.00) during mid-day trading on Thursday, reaching GBX 1.95 ($0.03). The company’s stock had a trading volume of 1,114,132 shares, compared to its average volume of 2,210,000. ReNeuron Group has a 52 week low of GBX 1.58 ($0.02) and a 52 week high of GBX 3.67 ($0.05).

TRADEMARK VIOLATION WARNING: “ReNeuron Group plc (LON:RENE) Stock Rating Reaffirmed by Stifel Nicolaus” was posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this piece can be accessed at

About ReNeuron Group

ReNeuron Group plc is a clinical-stage company. The Company, through its subsidiaries, is engaged in researching and developing cell-based therapies. The Company’s products are allogeneic. Its CTX stem cell therapy is used for the treatment of patients left disabled by the effects of a stroke. Its human retinal progenitor cells (hRPC) stem cell candidate is used for the treatment of retinitis pigmentosa (RP).

Receive News & Ratings for ReNeuron Group plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReNeuron Group plc and related companies with's FREE daily email newsletter.

Leave a Reply